A Study to Evaluate the Efficacy and Safety of QLF31907 Combination Therapy in Patients With Advanced Malignant Tumors

Exclusion Criteria

• •1. previous treatment with 4-1BB agonist or 4-1BB recombinant fusion protein;
• •2. received anti-tumor therapy within 4 weeks prior to the first study treatment;
• •3. history of autoimmune disease;
• •4. history of other active malignancies within 3 years prior to the first treatment;
• •5. history of serous cardiovascular events;